Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Mario Ponce; Cesar Ugarte-Gil; Carlos Zamudio; Fiorella Krapp; Eduardo Gotuzzo; Carlos Seas

doi:10.1016/j.trstmh.2012.05.008

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt
Hospital Nacional Cayetano Heredia

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

8 Citas (Scopus)

Resumen

The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.

Idioma original	Inglés
Páginas (desde-hasta)	508-510
Número de páginas	3
Publicación	Transactions of the Royal Society of Tropical Medicine and Hygiene
Volumen	106
N.º	8
DOI	https://doi.org/10.1016/j.trstmh.2012.05.008
Estado	Publicada - ago. 2012

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1016/j.trstmh.2012.05.008

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{fc459bdb81604778b7e61f20bb5561a8,

title = "Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru",

abstract = "The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85\% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1\% and 20.7\%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8\% (95\% CI: 58.9-75.6.) vs 77.8\% (95\% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.",

keywords = "Drug therapy, Failure, Multi-drug resistance, Streptomycin, Treatment outcome, Tuberculosis",

author = "Mario Ponce and Cesar Ugarte-Gil and Carlos Zamudio and Fiorella Krapp and Eduardo Gotuzzo and Carlos Seas",

year = "2012",

month = aug,

doi = "10.1016/j.trstmh.2012.05.008",

language = "Ingl{\'e}s",

volume = "106",

pages = "508--510",

journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",

issn = "0035-9203",

number = "8",

}

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru. / Ponce, Mario; Ugarte-Gil, Cesar ; Zamudio, Carlos et al.
En: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 106, N.º 8, 08.2012, p. 508-510.

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

TY - JOUR

T1 - Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

AU - Ponce, Mario

AU - Ugarte-Gil, Cesar

AU - Zamudio, Carlos

AU - Krapp, Fiorella

AU - Gotuzzo, Eduardo

AU - Seas, Carlos

PY - 2012/8

Y1 - 2012/8

N2 - The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.

AB - The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.

KW - Drug therapy

KW - Failure

KW - Multi-drug resistance

KW - Streptomycin

KW - Treatment outcome

KW - Tuberculosis

UR - https://www.scopus.com/pages/publications/84863579155

U2 - 10.1016/j.trstmh.2012.05.008

DO - 10.1016/j.trstmh.2012.05.008

M3 - Artículo

C2 - 22742941

AN - SCOPUS:84863579155

SN - 0035-9203

VL - 106

SP - 508

EP - 510

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

IS - 8

ER -

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto